ASCO 2026: MajesTEC-9 Clinical Trial Results @checkrare
ASCO 2026: MajesTEC-9 Clinical Trial Results  @checkrare
Uploaded July 2026 | Updated November 2026, 5 days ago
Roberto Mina, MD, Assistant Professor at Winship Cancer Institute at Emory University, discusses results from the MajesTEC-9 and CARTITUDE-4 clinical trials in patients with relapsed/refractory multiple myeloma (RRMM).

MM is a rare blood cancer characterized by the expansion of malignant plasma cells in the bone marrow associated with excessive production of monoclonal immunoglobulins in blood and urine. Individuals with multiple myeloma develop significant osteolytic bone lesions and have immunodeficiency that compromise their longevity and quality of life. The exact underlying cause of disease is currently unknown. Most patients with MM require multiple lines of therapy as patients are prone to relapse and/or refractory to therapy.

MajesTEC‑9 Phase 3 Results

MajesTEC-9 (NCT05572515) is a phase 3 randomized clinical trial comparing teclistamab monotherapy, a bispecific T-cell engager (BiTe) antibody, versus pomalidomide, bortezomib, dexamethasone (PVd) or carfilzomib, dexamethasone (Kd) in patients with relapsed or refractory MM who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and lenalidomide.

A total of 593 patients were randomized and had a median follow-up of 17.3 months. Teclistamab was observed to significantly improve both progression free survival and overall survival versus PVd/Kd. Of 174 patients treated with PVd/Kd who received subsequent treatment, 68.4% received BsAb or CAR-T. Progression free survival favored teclistamab across all prespecified subgroups, including anti-CD38-refractory patients and len-refractory patients. Complete response or better rate was significantly higher with teclistamab versus PVd/Kd.

At data cutoff, 65.3% of patients remained on teclistamab versus 24.0% on PVd/Kd. Treatment emergent adverse events were similar for teclistamab and PVd/Kd. Grade 3/4 adverse events (84.9% vs 76.3%) and grade 5 adverse events (6.5% vs 3.5%) were higher with teclistamab vs PVd/Kd, noting the median treatment duration was 13.1 months with teclistamab 7.0 months with PVd/Kd. Treatment discontinuation lower with teclistamab versuss PVd/Kd. CRS occurred in 66.0% of pts with teclistamab and ICANS in 4.1%.
ASCO 2026: MajesTEC-9 Clinical Trial ResultsTaletrectinib for ROS1-Positive Non-Small Cell Lung CancerBreakthrough Therapy Designation to Cimzia for Antiphospholipid SyndromeASCO 2026: CARTITUDE-4 Cytogenetic Subgroup AnalysisDermiselagon Development for EPP and XLPFDA Approves New Therapies for MPS IIIA and SMABreakthrough Therapy Designation to Cimzia for Pregnancy Complications in Antiphospholipid SyndromeEfficacy of Vosoritide to Treat HypochondroplasiaCh 5: Urgency of Diagnosis and Treatment in C3GAddressing Patient Experiences With IgA NephropathyCommon Concerns in Patients With Fabry DiseasePrader-Willi Syndrome: Diazoxide Choline Extended Release Improves Hyperphagia
CheckRare |

ASCO 2026: MajesTEC-9 Clinical Trial Results

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER